Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

disability progression

4 posts
RRoche
Roche's Fenebrutinib Shows Promising Results in Late-Stage Trial for Multiple Sclerosis, ETPharma
Read More

Roche’s Fenebrutinib Shows Promising Results in Late-Stage Trial for Multiple Sclerosis, ETPharma

  • 2026-02-20
Berlin: Swiss pharmaceutical company Roche ‍said on Saturday its experimental multiple sclerosis drug fenebrutinib ⁠met the main goal…
RRoche
Wall Street Just Woke Up to Roche--Here's Why It Could Be Pharma's Next $10 Billion Breakout
Read More

Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market

  • 2026-02-18
This article first appeared on GuruFocus. Roche Holding (RHHBF) could be entering a new growth chapter after unveiling…
RRoche
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Read More

Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?

  • 2026-02-18
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial

  • 2026-02-17
Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
Switzerland
www.europesays.com